liposomal paclitaxel + capecitabine

Liposomal paclitaxel + capecitabine is a combination chemotherapy regimen used primarily in the treatment of various solid tumors, including breast cancer and gastric cancer. Liposomal paclitaxel (L-PTX) is a formulation of the microtubule-stabilizing agent paclitaxel encapsulated in liposomes to improve drug delivery to tumor tissue and reduce toxicity compared to conventional formulations. Paclitaxel acts by binding to the β subunit of tubulin and stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis[4][5][6]. Capecitabine is an oral prodrug that is selectively converted by thymidine phosphorylase into 5-fluorouracil (5-FU) within tumor cells; 5-FU then inhibits DNA synthesis by interfering with thymidylate synthase activity[1][2]. The combination leverages complementary mechanisms—microtubule stabilization and inhibition of DNA synthesis—to enhance antitumor efficacy.

Other names

L-PTXpaclitaxel liposomecapecitabine